$1.14
+0.09 (+8.57%)
Open$1.06
Previous Close$1.05
Day High$1.14
Day Low$1.05
52W High$6.09
52W Low$2.58
Volume—
Avg Volume670.6K
Market Cap131.50M
P/E Ratio20.20
EPS$0.23
SectorBiotechnology
Analyst Ratings
Buy
18 analysts
Price Target
+404.4% upside
Current
$1.14
$1.14
Target
$5.75
$5.75
$4.43
$5.75 avg
$6.69
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 39.34M | 39.14M | 43.52M |
| Net Income | -9,457,413 | -10,010,485 | -9,808,127 |
| Profit Margin | -24.0% | -25.6% | -22.5% |
| EBITDA | -15,185,010 | -16,322,152 | -16,265,725 |
| Free Cash Flow | -7,860,846 | -10,981,777 | -9,671,173 |
| Rev Growth | +1.5% | +22.5% | +8.4% |
| Debt/Equity | 0.34 | 0.27 | 0.31 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $223.43 | +2.01% | 165.4 | 394.89B |
| AMGN | Amgen Inc | $384.32 | +4.49% | 26.8 | 206.95B |
| GILD | Gilead Sciences Inc | $152.50 | +2.10% | 23.3 | 189.20B |
| VRTX | Vertex Pharmaceuticals Inc | $477.92 | +4.17% | 33.7 | 123.82B |
| REGN | Regeneron Pharmaceuticals | $785.51 | +2.46% | 18.4 | 83.03B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.16 | -0.93% | 995.2 | 43.35B |